264 related articles for article (PubMed ID: 32133333)
21. Burosumab for Pediatric X-Linked Hypophosphatemia.
Imel EA
Curr Osteoporos Rep; 2021 Jun; 19(3):271-277. PubMed ID: 33970403
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of burosumab compared with conventional therapy in patients with X-linked hypophosphatemia: A systematic review.
Dodamani MH; Kumar SC; Bhattacharjee S; Barnabas R; Kumar S; Ranjan Lila A; Samad Memon S; Karlekar M; A Patil V; R Bandgar T
Arch Endocrinol Metab; 2024 May; 68():e230242. PubMed ID: 38788147
[TBL] [Abstract][Full Text] [Related]
23. Real-world effectiveness of burosumab in children with X-linked hypophosphatemic rickets.
Paloian NJ; Nemeth B; Sharafinski M; Modaff P; Steiner RD
Pediatr Nephrol; 2022 Nov; 37(11):2667-2677. PubMed ID: 35211790
[TBL] [Abstract][Full Text] [Related]
24. Persistent Lower Limb Deformities Despite Amelioration of Rickets in X-Linked Hypophosphatemia (XLH) - A Prospective Observational Study.
Mindler GT; Stauffer A; Kranzl A; Penzkofer S; Ganger R; Radler C; Haeusler G; Raimann A
Front Endocrinol (Lausanne); 2022; 13():866170. PubMed ID: 35399930
[TBL] [Abstract][Full Text] [Related]
25. Sex differences of burosumab in children with X-linked hypophosphataemic rickets.
Filler G; Tremblay O; Chen E; Huang SSH; Stein R
Pediatr Nephrol; 2023 Sep; 38(9):3183-3187. PubMed ID: 36542147
[TBL] [Abstract][Full Text] [Related]
26. The efficacy and safety of burosumab in two patients with cutaneous skeletal hypophosphatemia syndrome.
Sugarman J; Maruri A; Hamilton DJ; Tabatabai L; Luca D; Cimms T; Krolczyk S; Roberts MS; Carpenter TO
Bone; 2023 Jan; 166():116598. PubMed ID: 36341949
[TBL] [Abstract][Full Text] [Related]
27. Clinical guidelines for burosumab in the treatment of XLH in children and adolescents: British paediatric and adolescent bone group recommendations.
Padidela R; Cheung MS; Saraff V; Dharmaraj P
Endocr Connect; 2020 Oct; 9(10):1051-1056. PubMed ID: 33112809
[TBL] [Abstract][Full Text] [Related]
28. Burosumab vs conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension period.
Ward LM; Högler W; Glorieux FH; Portale AA; Whyte MP; Munns CF; Nilsson O; Simmons JH; Padidela R; Namba N; Cheong HI; Sochett E; Muroya K; Tanaka H; Pitukcheewanont P; Gottesman GS; Biggin A; Perwad F; Chen A; Lawrence Merritt Ii J; Imel EA
JBMR Plus; 2024 Jan; 8(1):ziad001. PubMed ID: 38690124
[TBL] [Abstract][Full Text] [Related]
29. Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries.
Mughal MZ; Baroncelli GI; de Lucas-Collantes C; Linglart A; Magnolato A; Raimann A; Santos F; Schnabel D; Shaw N; Nilsson O
Front Endocrinol (Lausanne); 2022; 13():1034580. PubMed ID: 36798486
[TBL] [Abstract][Full Text] [Related]
30. Switching to burosumab from conventional therapy in siblings with relatively well-controlled X-linked hypophosphatemia.
Senoo S; Fujimoto M; Yamaguchi Y; Osaki M; Hanaki K; Namba N
Clin Pediatr Endocrinol; 2024; 33(1):27-34. PubMed ID: 38299174
[TBL] [Abstract][Full Text] [Related]
31. Dramatic Transformation After Burosumab in a Young Boy With X-linked Hypophosphatemia: A Life-Changing Saga.
Baradhi K
Cureus; 2022 Feb; 14(2):e22340. PubMed ID: 35371638
[TBL] [Abstract][Full Text] [Related]
32. Self-Administration of Burosumab in Children and Adults with X-Linked Hypophosphataemia in Two Open-Label, Single-Arm Clinical Studies.
Kubota T; Namba N; Tanaka H; Muroya K; Imanishi Y; Takeuchi Y; Kanematsu M; Sun W; Seino Y; Ozono K
Adv Ther; 2023 Apr; 40(4):1530-1545. PubMed ID: 36719566
[TBL] [Abstract][Full Text] [Related]
33. Burosumab and Dental Abscesses in Children With X-Linked Hypophosphatemia.
Gadion M; Hervé A; Herrou J; Rothenbuhler A; Smail-Faugeron V; Courson F; Linglart A; Chaussain C; Biosse Duplan M
JBMR Plus; 2022 Nov; 6(11):e10672. PubMed ID: 36398111
[TBL] [Abstract][Full Text] [Related]
34. Burosumab in X-linked hypophosphatemia and perspective for chronic kidney disease.
Balani S; Perwad F
Curr Opin Nephrol Hypertens; 2020 Sep; 29(5):531-536. PubMed ID: 32701599
[TBL] [Abstract][Full Text] [Related]
35. Dental health of pediatric patients with X-linked hypophosphatemia (XLH) after three years of burosumab therapy.
Brener R; Zeitlin L; Lebenthal Y; Brener A
Front Endocrinol (Lausanne); 2022; 13():947814. PubMed ID: 36051396
[TBL] [Abstract][Full Text] [Related]
36. Real-world non-interventional post-authorization safety study of long-term use of burosumab in children and adolescents with X-linked hypophosphatemia: first interim analysis.
M Boot A; Ariceta G; Beck-Nielsen SS; Brandi ML; Briot K; Collantes CL; Giannini S; Haffner D; Keen R; Levtchenko E; Mughal MZ; Makitie O; Nilsson O; Schnabel D; Tripto-Shkolnik L; Zillikens MC; Liu J; Tudor A; Emma F
Ther Adv Chronic Dis; 2024; 15():20406223241247643. PubMed ID: 38764445
[TBL] [Abstract][Full Text] [Related]
37. Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor-Induced Osteomalacia.
Imanishi Y; Ito N; Rhee Y; Takeuchi Y; Shin CS; Takahashi Y; Onuma H; Kojima M; Kanematsu M; Kanda H; Seino Y; Fukumoto S
J Bone Miner Res; 2021 Feb; 36(2):262-270. PubMed ID: 32967046
[TBL] [Abstract][Full Text] [Related]
38. Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children.
Schindeler A; Biggin A; Munns CF
Front Endocrinol (Lausanne); 2020; 11():338. PubMed ID: 32547492
[TBL] [Abstract][Full Text] [Related]
39. Long-term Burosumab Administration Is Safe and Effective in Adults With X-linked Hypophosphatemia.
Weber TJ; Imel EA; Carpenter TO; Peacock M; Portale AA; Hetzer J; Merritt JL; Insogna K
J Clin Endocrinol Metab; 2022 Dec; 108(1):155-165. PubMed ID: 36072994
[TBL] [Abstract][Full Text] [Related]
40. Post-authorisation safety study of burosumab use in paediatric, adolescent and adult patients with X-linked hypophosphataemia: rationale and description.
Brandi ML; Ariceta G; Beck-Nielsen SS; Boot AM; Briot K; de Lucas Collantes C; Emma F; Giannini S; Haffner D; Keen R; Levtchenko E; Mӓkitie O; Nilsson O; Schnabel D; Tripto-Shkolnik L; Zillikens MC; Liu J; Tudor A; Mughal MZ
Ther Adv Chronic Dis; 2022; 13():20406223221117471. PubMed ID: 36082134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
